NervGen Pharma Corp. ("NervGen" or the "Company") , a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other ...
Completion of the Go-Public Transaction: On November 4, 2025, Summit completed its reverse takeover transaction of Eagle Royalties Ltd., and the Corporation’s common shares commenced trading on the ...
Summit Royalties Ltd. (TSXV: SUM) (the "Corporation" or "Summit") is pleased to provide a corporate update for 2025 and highlight upcoming 2026 catalysts. All ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback